PMI Announces Medicago to Supply Up to 76 Million Doses of Its Plant-Derived COVID-19 Vaccine Candidate
A Philip Morris International subsidiary is a shareholder in a biopharmaceutical company that reached agreements with two departments of the Canadian government to accelerate its COVID-19 vaccine candidate efforts
LAUSANNE, Switzerland--(BUSINESS WIRE)--Since 2008, Philip Morris Investments B.V. (PMIBV), a subsidiary of Philip Morris International (PMI) (NYSE: PM), has been a shareholder of Medicago (in which it currently holds an approximately one-third equity stake) and has supported Medicago’s innovative plant-derived research and development focused on vaccines. The investment is consistent with PMI’s own efforts to leverage science and innovation. Japan-based Mitsubishi Tanabe Pharma Corporation (MTPC) is the majority shareholder and PMIBV’s partner in Medicago. Among other things, PMIBV and MTPC will contribute additional funding to support Medicago’s efforts to develop a COVID-19 vaccine candidate.
Medicago, a biopharmaceutical company headquartered in Quebec City, announced that it reached an agreement with Public Services and Procurement Canada (PSPC) to supply up to 76 million doses of its vaccine candidate for COVID-19, subject to Health Canada approval. Innovation, Science & Economic Development (ISED), another department of the Canadian federal government, will contribute C$173M (or approximately $131M) to Medicago to support its on-going vaccine development and clinical trials, and for the construction of its Quebec City manufacturing facility.
PMI’s CEO André Calantzopoulos said: “We welcome the collaboration announced between two departments of the Canadian government and Medicago to accelerate its efforts against COVID-19. Better outcomes can be achieved when governments and companies join efforts to promote shared objectives for the greater good. We are pleased to be able to support Medicago’s work to develop, substantiate, manufacture, and make available a COVID-19 vaccine candidate. We all hope they will be successful.”
Medicago began Phase 1 testing on volunteers on July 14 and is anticipating that Phase 2 trials will begin in early November 2020. If Phase 2 trials are successful, Phase 3 trials are expected to begin in December 2020.
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships a version of its IQOS Platform 1 device and its consumables to Altria Group, Inc. for sale under license in the U.S., where the U.S. Food and Drug Administration (FDA) has authorized their marketing as a modified risk tobacco product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of September 30, 2020, PMI estimates that approximately 11.7 million adult smokers around the world have already stopped smoking and switched to PMI’s heat-not-burn product, available for sale in 61 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com.
Hyperice迈入全球发展新阶段
抖音带货必看!普通人带货爆单的秘诀!
联想在第7届Tech World全球科技创新年度
NetApp 发布软件数据服务更新,为数据中心带来
玫琳凯公布2022全年奖项、里程碑和成就
PMC Organometallix继续业务扩张
Enviva宣布与美国客户达成谅解备忘录
Andersen Global进驻哥伦比亚市场
道法自然 以人为本---李华坤
Sisvel向诺基亚授予Sisvel DSL专利许可
Visa和MFS Africa为非洲更多消费者和企业带去
联想集团:2021/22财年第三季度业绩
Allianz Survey: High Level
荣耀V Purse智能手机搭载 Elliptic Labs
研究加强人们对于不同原产国豆粕营养和经济差
雅诗兰黛公司宣布晋升品牌领导人员
“谢湖大樱桃”区域公用品牌形象正式发布
Visa令牌服务增加28家新合作伙伴,加强全球数字
Elliptic Labs宣布用于存在检测智能设备的虚拟智
商誉与企业并购的会计准则
Alliance Advisors任命大中华区投资者信息副总
Cervello Partners with ST En
Tetrate宣布在AWS Marketplace上推出
Visa拓展Fast Track计划,帮助新一代金融科技公司